上海交通大学学报(医学版)

• 论著(临床研究) • 上一篇    下一篇

18F-FDG-PET/CT早期预测复发转移非小细胞肺癌的缓解率和生存期的临床研究

徐海燕1,许远帆2,闫宁宁1,3,陈彬1,徐迎春4,刘建军2,5,张凤春1,3   

  1. 上海交通大学 医学院 1.附属苏州九龙医院肿瘤科, 苏州 215021; 2.附属苏州九龙医院核医学科, 苏州 215021; 3.附属瑞金医院肿瘤学科, 上海 200025; 4.附属仁济医院肿瘤科, 上海 200127; 5.附属仁济医院核医学科, 上海 200127
  • 出版日期:2015-11-28 发布日期:2016-01-13
  • 通讯作者: 张凤春, 电子信箱: fczhang2004@163.com。
  • 作者简介:徐海燕(1979—), 女, 主治医师, 硕士; 电子信箱: feelxu2001@163.com。
  • 基金资助:

    国家自然科学基金(81471687);上海市卫生局科研基金(201440606);国家卫计委科技发展项目(W2012FZ129)

Clinical study on the early prediction of the remission rate and survival of patients with recurrent metastatic NSCLC by 18F-FDG PET/CT

XU Hai-yan1, XU Yuan-fan2, YAN Ning-ning1,3, CHEN Bin1, XU Ying-chun4, LIU Jian-jun2,5, ZHANG Feng-chun1,3   

  1. 1.Department of Oncology, Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215021; 2.Department of Nuclear Medicine,Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215021; 3.Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025; 4.Department of Oncology, Renji Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200127; 5.Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127
  • Online:2015-11-28 Published:2016-01-13
  • Supported by:

    National Natural Science Foundation of China, 81471687; Scientific Research Foundation of Shanghai Municipal Health Bureau, 201440606; Science and Technology Development Project of National Health and Family Planning Commision of China, W2012FZ129

摘要:

目的  研究18氟脱氧葡萄糖正电子发射成像/电子计算机断层扫描(18F-FDG-PET/CT)早期预测复发转移非小细胞肺癌(NSCLC)缓解率与生存期的应用价值。方法  选择复发转移NSCLC患者24例,于化疗前和化疗后第1周期内分别行18F-FDG PET/CT显像。分析缓解(OR)组与未缓解(non-OR)组之间SUVmax1、SUVmax2、ΔSUVmax、SUVmax变化率的差异及代谢反应对生存期(OS)的影响。结果  OR组患者的ΔSUVmax(2.415±0.266)显著高于non-OR组(0.854±0.316),P=0.001 7;OR组SUVmax变化率(31.320±0.723)显著高于non-OR组(9.909±3.592),P<0.001。生存分析显示OR组患者的生存期较non-OR组的患者明显延长(P<0.05);代谢反应组患者的OS显著优于代谢无反应组的患者(P<0.05);且代谢反应组缓解率76.92%,无代谢反应组缓解率0%(χ2=13.901, P<0.001)。结论  18F-FDG PET/CT对复发转移NSCLC缓解率和生存期具有早期预测价值,仍需进一步临床研究验证。

关键词: PET/CT, 非小细胞肺癌, 代谢反应, 缓解率

Abstract:

Objective  To explore the application value of the 18F-FDG PET/CT for early prediction of the remission rate and survival of recurrent metastatic non-small cell lung cancer (NSCLC). Methods  A total of 24 patients with recurrent or metastatic NSCLC were selected. All patients underwent the PET/CT examination before and after the first cycle of chemotherapy. The differences of SUVmax1, SUVmax2, ΔSUVmax, and the change rate of SUVmax between the objective response (OR) group and non-objective response (non-OR) group were analyzed, as well as the effect of metabolic response on the overall survival (OS). Results  ΔSUVmax of the OR group (2.415±0.266) was significantly higher than that of the non-OR group (0.854±0.316, P=0.001 7). The change rate of SUVmax of the OR group (31.320±0.723) was remarkably higher than that of the non-OR group (9.909±3.592, P<0.001). The survival analysis showed that the overall survival of the OR group was obviously longer than that of the non-OR group (P<0.05). The overall survival of the metabolic response group was significantly longer than that of the non-metabolic response group (P<0.05). The remission response rates of the metabolic response group and non-metabolic response group were 76.92% and 0%, respectively (χ2=13.901, P<0.001). Conclusion  18F-FDG PET/CT is valuable for early prediction of the remission rate and survival of patients with recurrent or metastatic NSCLC and further clinical study and verification are needed.

Key words: PET/CT, NSCLC, metabolic response, response rate